Tg(tetO-NRAS*G12V,-CD2*)#Dle
Transgene Detail
|
|
| Symbol: |
Tg(tetO-NRAS*G12V,-CD2*)#Dle |
| Name: |
transgene insertion, David A Largaespada |
| MGI ID: |
MGI:4818795 |
| Synonyms: |
pTRE2-NRASV12-IRES-hCD2 |
| Transgene: |
Tg(tetO-NRAS*G12V,-CD2*)#Dle Location: unknown
|
| Alliance: |
Tg(tetO-NRAS*G12V,-CD2*)#Dle page
|
|
|
|
| Transgene Type: |
|
Transgenic (Humanized sequence, Inducible, Inserted expressed sequence) |
| Inducer: |
|
doxycycline/tetracycline |
| Mutation: |
|
Insertion
|
| |
|
Mutation details: The transgene is composed of TRE2, a tetracycline responsive element, the human NRAS coding sequence containing a G to V mutation at codon 12, followed by the EMCV IRES and a truncated human CD2 lacking the intracellular signaling portion of the molecule. Three independent founder lines of transgenic mice were established.
(J:101142)
|
|
|
|
|
| Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
| Carrying this Mutation: |
Mouse Strains: 0 strains available
Cell Lines: 0 lines available
|
|
| Original: |
J:101142 Wiesner SM, et al., Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse. Blood. 2005 Aug 1;106(3):1054-62 |
| All: |
4 reference(s) |
|
Analysis Tools
